Literature DB >> 76800

Antithrombin-III transfusion in disseminated intravascular coagulation.

H G Schipper, C S Jenkins, L H Kahlé, J W ten Cate.   

Abstract

Three patients with a severe bleeding disorder and disseminated intravascular coagulation were effectively treated with human antithrombin-III concentrates. This treatment, followed by administration of prothrombin complex and platelet suspensions, resulted in a normal haemostasis, which was maintained during clinical investigations and surgery.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 76800     DOI: 10.1016/s0140-6736(78)90196-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.

Authors:  R Scherer; M Kabatnik; J Erhard; J Peters
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

Review 2.  Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.

Authors:  S M Bates; J S Ginsberg; S E Straus; H Rekers; D L Sackett
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

3.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

4.  Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.

Authors:  R von Kries; H Stannigel; U Göbel
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

5.  Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition.

Authors:  A N Neely; R G Miller; I A Holder
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

7.  Low antithrombin III in neonatal shock: DIC or non-specific protein depletion?

Authors:  B K Schmidt; T Muraji; A Zipursky
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.